Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
171.2 USD | -2.74% | +3.86% | -4.75% |
May. 02 | UBS Adjusts Price Target on Repligen to $205 From $225, Maintains Buy Rating | MT |
May. 01 | Repligen's Q1 Adjusted Earnings, Revenue Fall | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.75% | 9.84B | |
-4.73% | 182B | |
+3.98% | 112B | |
-2.97% | 68.58B | |
+6.33% | 51.58B | |
+7.95% | 44.24B | |
+9.45% | 43.65B | |
+26.22% | 32.46B | |
+20.94% | 25.99B | |
+0.68% | 25.61B |
- Stock Market
- Equities
- RGEN Stock
- News Repligen Corporation
- Transcript : Repligen Corporation Presents at The Stifel 2023 Annual Healthcare Conference, Nov-15-2023 08